Literature DB >> 16860871

Management of vivax malaria with low sensitivity to primaquine.

K M B Ajdukiewicz1, E L C Ong.   

Abstract

Over the last two decades there have been numerous reports of primaquine failure in the treatment of Plasmodium vivax extending from the Western Pacific to South East Asia, India and Central and South America. In sub-Saharan Africa only five returning travellers have been reported with relapse of vivax malaria after primaquine and the absence of corroborating reports has prompted investigators to interpret their observations in terms of non-compliance. In 1997, 26 US military personnel serving in Somalia experienced attacks of P. vivax after terminal prophylaxis with primaquine. We have observed repeated relapses of P. vivax in two travellers, one to the Philippines and the other to Kenya despite both conventional and prolonged primaquine therapy. Here we report this clinical problem and propose a response to the emerging failure of the standard regimen of primaquine by considering the existing efficacy and toxicity data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860871     DOI: 10.1016/j.jinf.2006.05.008

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

Review 1.  Primaquine in vivax malaria: an update and review on management issues.

Authors:  Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  Malar J       Date:  2011-12-12       Impact factor: 2.979

Review 2.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

3.  A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.

Authors:  Toby Leslie; Ismail Mayan; Nasir Mohammed; Panna Erasmus; Jan Kolaczinski; Christopher J M Whitty; Mark Rowland
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.